A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of MLN9708 for the Treatment of Subjects With ISN / RPS Class III or IV Lupus Nephritis
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors Takeda
- 06 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Jun 2018.
- 06 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2018.
- 22 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2017 as reported by ClinicalTrials.gov.